Merck & Co., Inc. (NYSE:MRK) Shares Bought by CORDA Investment Management LLC.

CORDA Investment Management LLC. raised its stake in Merck & Co., Inc. (NYSE:MRK) by 10.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 317,480 shares of the company’s stock after acquiring an additional 30,586 shares during the quarter. Merck & Co., Inc. makes up 2.2% of CORDA Investment Management LLC.’s portfolio, making the stock its 19th biggest holding. CORDA Investment Management LLC.’s holdings in Merck & Co., Inc. were worth $24,474,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. NTV Asset Management LLC increased its stake in Merck & Co., Inc. by 22.8% in the fourth quarter. NTV Asset Management LLC now owns 24,982 shares of the company’s stock valued at $2,044,000 after purchasing an additional 4,643 shares during the last quarter. Sigma Planning Corp increased its stake in Merck & Co., Inc. by 15.3% in the first quarter. Sigma Planning Corp now owns 73,515 shares of the company’s stock valued at $5,667,000 after purchasing an additional 9,762 shares during the last quarter. Redpoint Investment Management Pty Ltd increased its stake in Merck & Co., Inc. by 3.6% in the first quarter. Redpoint Investment Management Pty Ltd now owns 67,844 shares of the company’s stock valued at $5,230,000 after purchasing an additional 2,377 shares during the last quarter. Alpha Cubed Investments LLC increased its stake in Merck & Co., Inc. by 9.8% in the first quarter. Alpha Cubed Investments LLC now owns 263,991 shares of the company’s stock valued at $20,351,000 after purchasing an additional 23,629 shares during the last quarter. Finally, Naples Global Advisors LLC increased its stake in Merck & Co., Inc. by 4.6% in the first quarter. Naples Global Advisors LLC now owns 81,214 shares of the company’s stock valued at $6,261,000 after purchasing an additional 3,578 shares during the last quarter. 71.98% of the stock is owned by institutional investors.

In other Merck & Co., Inc. news, EVP Frank Clyburn sold 19,324 shares of the firm’s stock in a transaction that occurred on Monday, May 10th. The stock was sold at an average price of $78.32, for a total value of $1,513,455.68. 0.32% of the stock is owned by company insiders.

Shares of Merck & Co., Inc. stock traded down $0.25 on Friday, reaching $75.89. The stock had a trading volume of 198,493 shares, compared to its average volume of 11,922,932. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.89. The business has a 50-day moving average price of $76.85. The company has a market capitalization of $192.16 billion, a PE ratio of 27.59, a P/E/G ratio of 1.84 and a beta of 0.40. Merck & Co., Inc. has a fifty-two week low of $71.71 and a fifty-two week high of $87.80.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 29th. The company reported $1.40 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.63 by ($0.23). The business had revenue of $12.08 billion during the quarter, compared to analyst estimates of $12.71 billion. Merck & Co., Inc. had a net margin of 14.64% and a return on equity of 54.15%. The company’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.50 earnings per share. On average, sell-side analysts forecast that Merck & Co., Inc. will post 6.47 earnings per share for the current year.

The business also recently announced a dividend, which was paid on Wednesday, June 2nd. Investors of record on Friday, June 4th were paid a $0.65 dividend. This represents a dividend yield of 3.42%. The ex-dividend date of this dividend was Thursday, June 3rd. Merck & Co., Inc.’s payout ratio is presently 43.77%.

MRK has been the subject of several analyst reports. JPMorgan Chase & Co. dropped their target price on Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday. Argus restated a “hold” rating on shares of Merck & Co., Inc. in a report on Thursday, May 20th. Truist Securities cut their price target on Merck & Co., Inc. from $96.00 to $93.00 and set a “buy” rating on the stock in a research note on Monday. Finally, SVB Leerink reduced their target price on Merck & Co., Inc. from $102.00 to $99.00 and set an “outperform” rating on the stock in a report on Thursday, June 3rd. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $96.11.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

Further Reading: Why is the price-sales ratio important?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.